Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272168 | 0.85 | KMT2A (1.00) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL17656854 | 0.84 | KMT2A (0.79) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL14032740 | 0.84 | HTT (0.82) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL14112019 | 0.83 | KMT2A (0.73) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL13458590 | 0.82 | KMT2A (0.67) | KMT2AHPGDSMN1; SMN2MEN1MAPT | |
| SCHEMBL29951626 | 0.81 | KMT2A (0.69) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL4781790 | 0.80 | LSS (0.74) | KMT2AHPGDMEN1L3MBTL1HTT | |
| SCHEMBL1695939 | 0.80 | KMT2A (0.88) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL14900387 | 0.80 | KMT2A (0.71) | KMT2AHPGDSMN1; SMN2MEN1L3MBTL1 | |
| SCHEMBL7606595 | 0.79 | KMT2A (0.70) | KMT2AHPGDMEN1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KRAS, NRAS, RASSF5 | KMT2A 1805/4885HPGD 3414/4885SMN1; SMN2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.